Krystal Biotech, Inc.
KRYS
$345.70
-$2.40-0.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 42.87% | 56.53% | 13.02% | 192.00% | 146.22% |
| Total Depreciation and Amortization | -32.60% | 14.51% | 67.47% | -3.21% | -63.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.06% | 3.83% | 26.07% | -195.27% | 10.69% |
| Change in Net Operating Assets | 1,037.85% | 154.41% | 267.80% | -253.20% | 101.48% |
| Cash from Operations | 41.84% | 159.56% | 46.68% | -32.62% | 1,365.09% |
| Capital Expenditure | -87.24% | -15.22% | -167.04% | -62.91% | -68.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,732.95% | -15.17% | 116.03% | 92.24% | 52.69% |
| Cash from Investing | -1,435.24% | -16.09% | 113.32% | 87.51% | 45.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 744.15% | 344.66% | 546.17% | 10.37% | -83.12% |
| Repurchase of Common Stock | -- | -21.77% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 738.14% | 16.10% | 545.22% | 10.22% | -83.12% |
| Foreign Exchange rate Adjustments | -272.90% | -878.36% | -7.24% | -207.34% | 414.24% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -263.28% | 113.88% | 456.35% | 37.60% | 440.84% |